Morphosys and Wacker will expand their cooperation in the use of Wacker’s bacterial secretion technology Esetec. As a result, MorphoSys will be able to use this technology for the production of antigen material in addition to the production of antibodies in both the early development phase of therapeutic projects as well as in the production of diagnostic and research antibodies.